Isis Pharmaceuticals (ISIS +2%) says it will receive $1.1M from Alnylam Pharmaceuticals (ALNY +0.2%) as its portion of the upfront fees in ALNY's recently announced collaboration with Genzyme. In addition, Isis has the potential to receive royalty payments and a portion of future milestone payments. Already this year, Isis has earned $2.7M from Alnylam as a result of licenses that were supported by Isis' patents.
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at Zacks.com (Fri, 7:14AM)
at Zacks.com (Mon, 10:40AM)
at Zacks.com (Feb 25, 2015)
at Nasdaq.com (Feb 5, 2015)
at Investor's Business Daily (Jan 16, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs